MYGN · Insider Trading
Myriad Genetics Inc
Every open-market purchase and sale reported by MYGN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-11-02 | Jennifer Lynne Fox | Chief Legal & Corp Strategy | A | +39,370 | — |
| 2026-09-22 | Benjamin Richard Wheeler | Chief Financial Officer | F | −2,555 | −$10.25K |
| 2026-09-18 | Brian J Donnelly | Chief Commercial Officer | — | — | — |
| 2026-09-17 | Vishal Sikri | EVP, Commercial | A | +257,731 | — |
| 2026-09-08 | Jennifer Lynne Fox | Chief Legal Officer | F | −4,398 | −$14.21K |
| 2026-08-17 | Benjamin Richard Wheeler | Chief Financial Officer | F | −8,761 | −$26.55K |
| 2026-06-23 | Daniel Skovronsky | Director | — | — | — |
| 2026-06-12 | Brian J Donnelly | Chief Commerical Officer | A | +5,000 | +$19.68K |
| 2026-06-12 | Samraat S. Raha | President and CEO | A | +3,542 | +$13.94K |
| 2026-06-09 | Rashmi Kumar | Director | Sell | −15,000 | −$66.84K |
| 2026-06-05 | Paul Bisaro | Director | A | +59,701 | — |
| 2026-06-05 | Colleen F Reitan | Director | A | +59,701 | — |
| 2026-06-05 | S. Louise Phanstiel | Director | A | +59,701 | — |
| 2026-06-05 | Rashmi Kumar | Director | A | +59,701 | — |
| 2026-06-05 | Mark Steven Davis | Director | A | +59,701 | — |
| 2026-06-05 | Heinrich Dreismann | Director | A | +59,701 | — |
| 2026-06-05 | Lee Nisley Newcomer | Director | A | +59,701 | — |
| 2026-06-05 | Daniel Skovronsky | Director | A | +59,701 | — |
| 2026-06-02 | Raj Jampa | Chief Technology Officer | A | +251,889 | — |
| 2026-05-14 | Paul Bisaro | Director | Buy | +7,500 | +$27.64K |
| 2026-05-04 | Brian J Donnelly | Chief Commerical Officer | F | −55,975 | −$268.68K |
| 2026-04-15 | Dale Muzzey | Chief Scientific Officer | F | −946 | −$4.64K |
| 2026-04-15 | Mark Verratti | Chief Operating Officer | F | −1,069 | −$5.25K |
| 2026-03-23 | Benjamin Richard Wheeler | Chief Financial Officer | F | −549 | −$2.51K |
| 2026-03-23 | Mark Verratti | Chief Operating Officer | F | −2,055 | −$9.41K |
| 2026-03-23 | Dale Muzzey | Chief Scientific Officer | F | −2,019 | −$9.25K |
| 2026-03-16 | Jennifer Lynne Fox | Chief Legal Officer | MIXED | +189,881 | −$27.94K |
| 2026-03-16 | Samraat S. Raha | President and CEO | MIXED | +571,437 | −$219.58K |
| 2026-03-16 | Shereen Solaiman | Chief People Officer | MIXED | +158,513 | −$68.42K |
| 2026-03-16 | Benjamin Richard Wheeler | Chief Financial Officer | MIXED | +201,434 | −$22.14K |
| 2026-03-16 | Mark Verratti | Chief Operating Officer | MIXED | +218,134 | −$136.49K |
| 2026-03-16 | Kevin Richard Haas | Chief Technology Officer | F | −22,310 | −$103.96K |
| 2026-03-16 | Dale Muzzey | Chief Scientific Officer | MIXED | +135,397 | −$176.14K |
| 2026-03-16 | Brian J Donnelly | Chief Commerical Officer | A | +226,804 | — |
| 2026-03-09 | Samraat S. Raha | President and CEO | Buy | +40,000 | +$199.84K |
| 2026-03-02 | Shereen Solaiman | Chief People Officer | F | −1,675 | −$7.72K |
| 2026-02-27 | S. Louise Phanstiel | Director | Buy | +104,507 | +$494.72K |
| 2026-02-03 | Dale Muzzey | Chief Scientific Officer | A | +23,697 | — |
| 2026-02-03 | Kevin Richard Haas | Chief Technology Officer | A | +23,697 | — |
| 2026-02-03 | Mark Verratti | Chief Operating Officer | A | +32,810 | — |
| 2026-02-03 | Benjamin Richard Wheeler | Chief Financial Officer | A | +4,994 | — |
| 2026-01-02 | Dale Muzzey | Chief Scientific Officer | F | −418 | −$2.57K |
| 2025-12-29 | Benjamin Richard Wheeler | Chief Financial Officer | F | −21 | −$138 |
| 2025-12-12 | Samraat S. Raha | President and CEO | F | −29,634 | −$216.33K |
| 2025-11-04 | Margaret Ancona | EVP, Strategy & Transformation | — | — | — |
| 2025-10-24 | Natalie Munk | Chief Accounting Officer | — | — | — |
| 2025-09-22 | Benjamin Richard Wheeler | Chief Financial Officer | F | −2,559 | −$19.88K |
| 2025-09-22 | Natalie Munk | Chief Accounting Officer | F | −962 | −$7.47K |
| 2025-09-22 | Margaret Ancona | EVP, Strategy & Transformation | F | −958 | −$7.44K |
| 2025-09-22 | Mark Verratti | Chief Operating Officer | F | −1,085 | −$8.43K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Samraat S. Raha | President and CEO | 1,068,083 | $6.15M |
| Paul J Diaz | President and CEO | 891,844 | $5.13M |
| Mark Verratti | Chief Operating Officer | 629,646 | $3.62M |
| Brian J Donnelly | Chief Commercial Officer | 573,363 | $3.30M |
| S. Louise Phanstiel | Director | 374,771 | $2.16M |
| Vishal Sikri | EVP, Commercial | 351,224 | $2.02M |
| Jennifer Lynne Fox | Chief Legal & Corp Strategy | 345,334 | $1.99M |
| Dale Muzzey | Chief Scientific Officer | 326,310 | $1.88M |
| Benjamin Richard Wheeler | Chief Financial Officer | 287,193 | $1.65M |
| Shereen Solaiman | Chief People Officer | 273,585 | $1.57M |
| Raj Jampa | Chief Technology Officer | 251,889 | $1.45M |
| Heinrich Dreismann | Director | 231,145 | $1.33M |
| Scott J. Leffler | Chief Financial Officer | 218,393 | $1.26M |
| Daniel Skovronsky | Director | 195,507 | $1.13M |
| Lee Nisley Newcomer | Director | 191,842 | $1.10M |
| Kevin Richard Haas | Chief Technology Officer | 191,759 | $1.10M |
| Rashmi Kumar | Director | 171,889 | $989.22K |
| Paul Bisaro | Director | 157,142 | $904.35K |
| Colleen F Reitan | Director | 152,030 | $874.93K |
| Margaret Ancona | EVP, Strategy & Transformation | 127,726 | $735.06K |
| Mark Steven Davis | Director | 106,665 | $613.86K |
| Natalie Munk | Chief Accounting Officer | 45,167 | $259.94K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the MYGN quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.